文献速递乳腺癌

节拍式口服长春瑞滨联合环磷酰胺和卡培他滨对比每周静脉紫杉醇治疗雌激素受体阳性、ERBB2阴性转移性乳腺癌的疗效:2期METEORA-II随机临床试验最终结果

Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项在意大利15个中心开展的2期随机临床试验纳入140例雌激素受体阳性、ERBB2阴性转移性乳腺癌女性,比较节拍式口服长春瑞滨联合环磷酰胺和卡培他滨(VEX)方案与每周静脉紫杉醇的疗效。VEX组较紫杉醇组显著延长至治疗失败时间(中位8.3个月 vs 5.7个月,HR 0.61,P=0.008)和无进展生存期(中位11.1个月 vs 6.9个月,HR 0.67,P=0.03),总生存无差异,VEX组3/4级靶向不良事件更多但脱发基本没有。

要点

  • VEX组中位至治疗失败时间为8.3个月,紫杉醇组为5.7个月(HR 0.61,95%CI 0.42-0.88,P=0.008)。
  • VEX组中位无进展生存期为11.1个月,紫杉醇组为6.9个月(HR 0.67,95%CI 0.46-0.96,P=0.03)。
  • 两组总生存无差异;VEX组至少1次3/4级靶向不良事件发生率为42.9%,紫杉醇组为28.6%。

核心结论

  • 该随机临床试验发现,口服VEX方案较静脉紫杉醇显著延长至治疗失败时间和无进展生存期,但总生存无改善,毒性增加但仍可控。
  • 作者认为,对于雌激素受体阳性、ERBB2阴性转移性乳腺癌,VEX方案可能比每周紫杉醇提供更长的疾病控制。

研究设计与样本

  • 2期随机临床试验,2017年9月13日至2021年1月14日在意大利15个中心开展,纳入140例18岁及以上雌激素受体阳性、ERBB2阴性转移性乳腺癌女性,按1:1随机分组。
  • 入组患者允许既往接受过1线转移性乳腺癌化疗和/或2线内分泌治疗(包括CDK4/6抑制剂)。
  • 干预为4周周期:节拍式口服VEX方案或每周静脉紫杉醇;实际接受治疗者VEX组70例、紫杉醇组63例。
  • 主要终点为研究者评估的至治疗失败时间,定义为从随机化日期至治疗结束(因疾病进展、耐受性差或拒绝继续试验治疗)的间隔。
  • 次要终点包括无进展生存期、总生存期和疾病控制率(完全或部分缓解或持续至少24周的疾病稳定)。

主要发现

  • VEX组较紫杉醇组显著延长至治疗失败时间(HR 0.61,95%CI 0.42-0.88,P=0.008),中位至治疗失败时间VEX组8.3个月(95%CI 5.6-11.1)vs 紫杉醇组5.7个月(95%CI 4.1-6.1),12个月至治疗失败率VEX组34.3% vs 紫杉醇组8.6%。
  • VEX组较紫杉醇组显著延长无进展生存期(HR 0.67,95%CI 0.46-0.96,P=0.03),中位无进展生存期VEX组11.1个月(95%CI 8.3-13.8)vs 紫杉醇组6.9个月(95%CI 5.4-10.1),12个月无进展生存率VEX组43.5% vs 紫杉醇组21.9%。
  • 两组总生存无差异。
  • 55.6%患者的治疗失败事件为疾病进展,23%为不良事件。
  • VEX组至少1次3/4级靶向不良事件发生率42.9%(95%CI 31.1%-55.3%)vs 紫杉醇组28.6%(95%CI 17.9%-41.3%),VEX组基本无脱发。

临床怎么用

  • 作者认为,对于雌激素受体阳性、ERBB2阴性转移性乳腺癌,VEX方案可能比每周紫杉醇提供更长的疾病控制。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In spite of the effectiveness of endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as the first-line treatment for estrogen receptor (ER)-positive, erb-b2 receptor tyrosine kinase 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and eventually most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral treatment with intravenous (IV) chemotherapy. OBJECTIVE: To compare the efficacy of the oral vinorelbine plus cyclophosphamide plus capecitabine (VEX) regimen vs weekly IV paclitaxel among patients with ER+/ERBB2- MBC who are candidates for chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial including 140 women 18 years and older (randomized 1:1) with ER+/ERBB2- MBC was carried out from September 13, 2017, to January 14, 2021 at 15 centers in Italy. Eligible patients could have received 1 prior line of chemotherapy for MBC and/or 2 lines of endocrine therapy (including CDK4/6 inhibitors). INTERVENTIONS: In 4-week cycles, patients received either metronomic oral VEX or weekly IV paclitaxel. MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed time to treatment failure (TTF) defined as the interval between the date of randomization to the end of treatment (because of disease progression or lack of tolerability or because further trial treatment was declined). Secondary end points included progression-free survival (PFS), overall survival (OS), and disease control rate (complete or partial response or stable disease lasting for at least 24 weeks). RESULTS: In total, 133 patients received either VEX (n = 70) or paclitaxel (n = 63) in 4-weekly cycles. The median age was 61 (range, 30-80) years. The VEX treatment significantly prolonged TTF vs paclitaxel (hazard ratio [HR], 0.61; 95% CI, 0.42-0.88; P = .008), median TTF was 8.3 (95% CI, 5.6-11.1) months for VEX vs 5.7 (95% CI, 4.1-6.1) months for paclitaxel, and the 12-month TTF was 34.3% for VEX vs 8.6% for paclitaxel. The median PFS was 11.1 (95% CI, 8.3-13.8) months vs 6.9 (95% CI, 5.4-10.1) months favoring VEX (HR, 0.67; 95% CI, 0.46-0.96, P = .03). The 12-month PFS was 43.5% for VEX vs 21.9% for paclitaxel. No difference in OS was found. The TF event for 55.6% of patients was progression of disease; for 23% it was AEs. More patients assigned to VEX had at least 1 grade 3 or 4 targeted adverse event (VEX, 42.9%; 95% CI, 31.1%-55.3% vs paclitaxel, 28.6%; 95% CI, 17.9%-41.3%), but essentially no alopecia. CONCLUSION AND RELEVANCE: This randomized clinical trial found significantly prolonged TTF and PFS for oral VEX but no improvement in OS compared with intravenous paclitaxel, despite increased but still manageable toxic effects. The VEX regimen may provide more prolonged disease control than weekly paclitaxel for ER+/ERBB2- MBC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02954055.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Munzone E, Regan MM, Cinieri S, et al. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37440239. doi:10.1001/jamaoncol.2023.2150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。